PL2770822T3 - Genetycznie zmodyfikowane cząsteczki, w których zachodzi ekspresja chimerycznego głównego układu zgodności tkankowej (mhc) ii myszy - Google Patents
Genetycznie zmodyfikowane cząsteczki, w których zachodzi ekspresja chimerycznego głównego układu zgodności tkankowej (mhc) ii myszyInfo
- Publication number
- PL2770822T3 PL2770822T3 PL12806199T PL12806199T PL2770822T3 PL 2770822 T3 PL2770822 T3 PL 2770822T3 PL 12806199 T PL12806199 T PL 12806199T PL 12806199 T PL12806199 T PL 12806199T PL 2770822 T3 PL2770822 T3 PL 2770822T3
- Authority
- PL
- Poland
- Prior art keywords
- mhc
- molecules
- genetically modified
- major histocompatibility
- histocompatibility complex
- Prior art date
Links
- 108700018351 Major Histocompatibility Complex Proteins 0.000 title 1
- 241000699670 Mus sp. Species 0.000 title 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161552584P | 2011-10-28 | 2011-10-28 | |
| EP12806199.1A EP2770822B9 (en) | 2011-10-28 | 2012-10-26 | Genetically modified mice expressing chimeric major histocompatibility complex (mhc) ii molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2770822T3 true PL2770822T3 (pl) | 2017-11-30 |
Family
ID=47430036
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17171524T PL3272214T3 (pl) | 2011-10-28 | 2012-10-26 | Genetycznie zmodyfikowane cząsteczki, w których zachodzi ekspresja chimerycznego głównego układu zgodności tkankowej (MHC) II myszy |
| PL12806199T PL2770822T3 (pl) | 2011-10-28 | 2012-10-26 | Genetycznie zmodyfikowane cząsteczki, w których zachodzi ekspresja chimerycznego głównego układu zgodności tkankowej (mhc) ii myszy |
| PL19189533T PL3590332T3 (pl) | 2011-10-28 | 2012-10-26 | Genetycznie zmodyfikowane myszy eksprymujące chimeryczne cząsteczki głównego układu zgodności tkankowej (MHC) II |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17171524T PL3272214T3 (pl) | 2011-10-28 | 2012-10-26 | Genetycznie zmodyfikowane cząsteczki, w których zachodzi ekspresja chimerycznego głównego układu zgodności tkankowej (MHC) II myszy |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19189533T PL3590332T3 (pl) | 2011-10-28 | 2012-10-26 | Genetycznie zmodyfikowane myszy eksprymujące chimeryczne cząsteczki głównego układu zgodności tkankowej (MHC) II |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8847005B2 (enExample) |
| EP (4) | EP3272214B1 (enExample) |
| JP (2) | JP6285361B2 (enExample) |
| KR (2) | KR101926442B1 (enExample) |
| CN (3) | CN104039133B (enExample) |
| AU (4) | AU2012327205B2 (enExample) |
| BR (1) | BR112014009941B1 (enExample) |
| CA (1) | CA2852962C (enExample) |
| CY (3) | CY1119283T1 (enExample) |
| DK (3) | DK2770822T3 (enExample) |
| ES (3) | ES2774488T3 (enExample) |
| HR (3) | HRP20171327T1 (enExample) |
| HU (2) | HUE034374T2 (enExample) |
| IL (3) | IL231895B (enExample) |
| IN (1) | IN2014CN03892A (enExample) |
| LT (3) | LT2770822T (enExample) |
| MX (2) | MX379060B (enExample) |
| PL (3) | PL3272214T3 (enExample) |
| PT (3) | PT3590332T (enExample) |
| RS (3) | RS56330B1 (enExample) |
| RU (1) | RU2660564C2 (enExample) |
| SG (3) | SG10201510056SA (enExample) |
| SI (3) | SI2770822T1 (enExample) |
| SM (3) | SMT201700437T1 (enExample) |
| WO (1) | WO2013063340A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008054865A2 (en) | 2006-04-26 | 2008-05-08 | L-3 Communications Security And Detection Systems, Inc. | Multi-source surveillance systems |
| CN104039133B (zh) | 2011-10-28 | 2018-05-04 | 瑞泽恩制药公司 | 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠 |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CA2853731C (en) | 2011-10-28 | 2021-05-18 | Regeneron Pharmaceuticals, Inc. | Humanized il-6 and il-6 receptor |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| EP4249507A3 (en) * | 2013-03-11 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| KR102370419B1 (ko) | 2013-09-23 | 2022-03-04 | 리제너론 파마슈티칼스 인코포레이티드 | 인간화된 신호-조절 단백질 유전자를 가지는 비-인간 동물 |
| ES2715949T3 (es) * | 2013-10-15 | 2019-06-07 | Regeneron Pharma | Animales con IL-15 humanizada |
| WO2015077071A1 (en) | 2013-11-19 | 2015-05-28 | Regeneron Pharmaceuticals, Inc. | Non-human animals having a humanized b-cell activating factor gene |
| DK3129400T3 (da) | 2014-04-08 | 2020-06-08 | Regeneron Pharma | Ikke-humane dyr med humaniserede Fc-gamma-receptorer |
| NO2785538T3 (enExample) | 2014-05-07 | 2018-08-04 | ||
| BR112016029650A2 (pt) * | 2014-06-19 | 2017-10-24 | Regeneron Pharma | roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor? |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| PL3689140T3 (pl) | 2014-11-24 | 2022-09-05 | Regeneron Pharmaceuticals, Inc. | Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3 |
| IL286403B2 (en) | 2014-12-05 | 2023-10-01 | Regeneron Pharma | Non-human animals possess a humanized CLUSTER OF DIFFERENTIATION 47 gene |
| HUE067123T2 (hu) | 2014-12-09 | 2024-10-28 | Regeneron Pharma | Humanizált differenciációs klaszter 274 génnel rendelkezõ nem humán állatok |
| CN107666828B (zh) | 2015-04-06 | 2021-04-09 | 瑞泽恩制药公司 | 非人动物中的人源化t细胞介导的免疫应答 |
| JP6997708B2 (ja) | 2015-11-20 | 2022-02-04 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ヒト化されたｌｙｍｐｈｏｃｙｔｅ－ａｃｔｉｖａｔｉｏｎ ｇｅｎｅ ３遺伝子を有する非ヒト動物 |
| SG11201806176PA (en) * | 2016-02-04 | 2018-08-30 | Regeneron Pharma | Non-human animals having an engineered angptl8 gene |
| AU2017228293B2 (en) | 2016-02-29 | 2023-05-25 | Regeneron Pharmaceuticals, Inc. | Rodents having a humanized Tmprss gene |
| RS66700B1 (sr) | 2016-06-03 | 2025-05-30 | Regeneron Pharma | Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu |
| IL274740B2 (en) | 2017-11-30 | 2024-06-01 | Regeneron Pharma | Non-human animals comprising a humanized trkb locus |
| EP3772927B1 (en) | 2018-03-24 | 2025-01-15 | Regeneron Pharmaceuticals, Inc. | Genetically modified mice or rats for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof |
| CA3093850A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Humanized rodents for testing therapeutic agents |
| FI3823443T3 (fi) | 2018-07-16 | 2024-07-25 | Regeneron Pharma | Ditra-taudin jyrsijämallit ja niiden käyttö |
| JP7685249B2 (ja) * | 2019-10-22 | 2025-05-29 | ザ・トラスティーズ・オブ・コロンビア・ユニバーシティ・イン・ザ・シティ・オブ・ニューヨーク | トランスジェニックブタ、その作製方法と用途、およびヒト免疫系マウスの作製方法 |
| JP7726881B2 (ja) | 2019-12-02 | 2025-08-20 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ペプチド－ｍｈｃ ｉｉタンパク質構築物およびそれらの使用 |
| JP2024512702A (ja) | 2021-03-31 | 2024-03-19 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔｃｒβレパートリーの改善された多様性を伴うヒト化細胞免疫系の構成要素を含む、遺伝的に改変されたマウス |
| WO2023240109A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules for modulating t-cell activity, and uses thereof |
| WO2023240124A1 (en) | 2022-06-07 | 2023-12-14 | Regeneron Pharmaceuticals, Inc. | Pseudotyped viral particles for targeting tcr-expressing cells |
| KR20250077529A (ko) | 2022-09-22 | 2025-05-30 | 리제너론 파아마슈티컬스, 인크. | 인간 세포 면역계의 성분을 발현하는, 유전자적으로 변형된 마우스 |
| EP4654982A1 (en) | 2023-01-27 | 2025-12-03 | Regeneron Pharmaceuticals, Inc. | Modified rhabdovirus glycoproteins and uses thereof |
| WO2025064470A1 (en) | 2023-09-19 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Viral peptides and uses thereof |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| WO2025136809A2 (en) | 2023-12-19 | 2025-06-26 | Regeneron Pharmaceuticals, Inc. | Foxp3 peptides and uses thereof |
| WO2025178991A1 (en) | 2024-02-21 | 2025-08-28 | Regeneron Pharmaceuticals, Inc. | Splicing factor gene mutation-associated neoantigenic peptides and uses thereof |
| WO2025212991A1 (en) | 2024-04-05 | 2025-10-09 | Regeneron Pharmaceuticals, Inc. | Rodent models of disease |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5574205A (en) | 1989-07-25 | 1996-11-12 | Cell Genesys | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| DE69034263D1 (de) | 1989-07-25 | 2009-04-02 | Cell Genesys Inc | Homologe Rekombination für universelle Donorzellen und chimerische Säugetierzellen |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| GB9100481D0 (en) | 1991-01-10 | 1991-02-20 | Inst Nat Sante Rech Med | Genetically engineered mice |
| WO1993005817A1 (en) | 1991-09-19 | 1993-04-01 | President And Fellows Of Harvard College | Transgenic mhc class i and class ii antigen-deficient mammals |
| WO1994006908A1 (en) | 1992-09-11 | 1994-03-31 | The Regents Of The University Of California | Transgenic non-human animals having targeted lymphocyte transduction genes |
| US5523226A (en) | 1993-05-14 | 1996-06-04 | Biotechnology Research And Development Corp. | Transgenic swine compositions and methods |
| GB9315303D0 (en) | 1993-07-23 | 1993-09-08 | Zeneca Ltd | Polypeptide |
| US5965787A (en) | 1995-08-31 | 1999-10-12 | Mayo Foundation For Medical Education And Research | HLA-DRBI peptides with specific binding affinity for HLA-DQ molecules: prevention and treatment of rheumatoid arthritis |
| US6002066A (en) | 1996-01-16 | 1999-12-14 | Ortho Pharmaceutical Corp. | H2-M modified transgenic mice |
| CA2246333A1 (en) | 1996-03-05 | 1997-09-12 | The Scripps Research Institute | Recombinant constructs encoding t cell receptors specific for human hla-restricted tumor antigens |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| DE69840600D1 (de) | 1997-09-16 | 2009-04-09 | Univ Oregon Health & Science | Rekombinante mhc-moleküle welche nützlich sind für die manipulation von antigen-spezifischen t-zellen |
| US6372955B1 (en) | 1998-02-17 | 2002-04-16 | Ortho Mcneil Pharmaceutical, Inc. | Methods for Producing B cells and antibodies from H2-O modified transgenic mice |
| US6147275A (en) * | 1998-03-30 | 2000-11-14 | Research Development Foundation | Corticotropin releasing factor receptor 1-deficient mice |
| WO2001027291A1 (en) | 1999-10-12 | 2001-04-19 | Institut Pasteur | Design of a polyepitopic construct for the induction of hla-a2.1 restricted hiv 1 specific ctl responses using hhd mice |
| US7067308B1 (en) * | 2000-03-28 | 2006-06-27 | Bioagri Corporation | Vector for genetically modifying non-human animals |
| US20030124524A1 (en) | 2000-06-23 | 2003-07-03 | Kenneth Kornman | Screening assays for identifying modulators of the inflammatory or immune response |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| WO2002047474A1 (en) | 2000-12-13 | 2002-06-20 | Sumitomo Pharmaceuticals Company, Limited | Transgenic animal expressing hla-a24 and utilization thereof |
| ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| FR2827302B1 (fr) | 2001-07-13 | 2003-10-10 | Genoway | Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations |
| US20040072262A1 (en) | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
| US7663017B2 (en) | 2003-07-30 | 2010-02-16 | Institut Pasteur | Transgenic mice having a human major histocompatability complex (MHC) phenotype, experimental uses and applications |
| DE10347710B4 (de) * | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| WO2005085438A1 (ja) | 2004-03-09 | 2005-09-15 | Nagoya Industrial Science Research Institute | ヒト関節リウマチの病態を再現するトランスジェニック非ヒト哺乳動物 |
| EP1802193B1 (en) | 2004-10-19 | 2014-04-30 | Regeneron Pharmaceuticals, Inc. | Method for generating a mouse homozygous for a genetic modification |
| EP1878342A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Immunodeficient mice transgenic for HLA class I and HLA class II molecules and their uses |
| EP1878798A1 (en) | 2006-07-13 | 2008-01-16 | Institut Pasteur | Method of producing a multichimeric mouse and applications to study the immunopathogenesis of human tissue-specific pathologies |
| HU0700534D0 (en) | 2006-11-24 | 2007-10-29 | Mezoegazdasagi Biotechnologiai | Transgenic animal with enhanced immune response and method for the preparation thereof |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| ES2665068T3 (es) | 2008-03-07 | 2018-04-24 | Regeneron Pharmaceuticals, Inc. | Ratones derivados de células ES a partir de inyección de un embrión hospedador diploide |
| US20090328240A1 (en) | 2008-06-24 | 2009-12-31 | Sing George L | Genetically modified mice as predictors of immune response |
| NO2792236T3 (enExample) | 2009-07-08 | 2018-04-14 | ||
| CN101695587B (zh) * | 2009-10-21 | 2012-08-29 | 上海中山医疗科技发展公司 | 一种基因修饰及调控的内皮祖细胞捕获支架的制备方法 |
| CA2805479A1 (en) | 2010-07-15 | 2012-01-19 | Technion Research & Development Foundation Ltd. | Isolated high affinity entities with t-cell receptor like specificity towards native complexes of mhc class ii and glutamic acid decarboxylase (gad) autoantigenic peptides |
| WO2012039779A1 (en) | 2010-09-24 | 2012-03-29 | The United States Of America As Represented By The Secretary Of The Navy | Humanized transgenic mouse model |
| US9043996B2 (en) | 2011-10-28 | 2015-06-02 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex animals |
| CN104039133B (zh) | 2011-10-28 | 2018-05-04 | 瑞泽恩制药公司 | 表达嵌合主要组织相容性复合物(mhc)ii类分子的基因修饰小鼠 |
| KR102714111B1 (ko) | 2013-02-20 | 2024-10-11 | 리제너론 파아마슈티컬스, 인크. | 사람화된 ｔ-세포 보조-수용체를 발현하는 마우스 |
| US20150342163A1 (en) | 2013-02-22 | 2015-12-03 | Regeneron Pharmaceuticals, Inc. | Genetically modified major histocompatibility complex mice |
| HRP20181866T1 (hr) | 2013-02-22 | 2019-01-25 | Regeneron Pharmaceuticals, Inc. | Miševi koji izražavaju humanizirane komplekse glavne histokompatibilnosti |
| EP4249507A3 (en) | 2013-03-11 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Transgenic mice expressing chimeric major histocompatibility complex (mhc) class ii molecules |
| CN107666828B (zh) | 2015-04-06 | 2021-04-09 | 瑞泽恩制药公司 | 非人动物中的人源化t细胞介导的免疫应答 |
-
2012
- 2012-10-26 CN CN201280065075.7A patent/CN104039133B/zh active Active
- 2012-10-26 PL PL17171524T patent/PL3272214T3/pl unknown
- 2012-10-26 PL PL12806199T patent/PL2770822T3/pl unknown
- 2012-10-26 DK DK12806199.1T patent/DK2770822T3/en active
- 2012-10-26 SM SM20170437T patent/SMT201700437T1/it unknown
- 2012-10-26 EP EP17171524.6A patent/EP3272214B1/en active Active
- 2012-10-26 LT LTEP12806199.1T patent/LT2770822T/lt unknown
- 2012-10-26 BR BR112014009941-3A patent/BR112014009941B1/pt active IP Right Grant
- 2012-10-26 EP EP12806199.1A patent/EP2770822B9/en active Active
- 2012-10-26 MX MX2017013492A patent/MX379060B/es unknown
- 2012-10-26 EP EP22152099.2A patent/EP4052572B1/en active Active
- 2012-10-26 LT LTEP19189533.3T patent/LT3590332T/lt unknown
- 2012-10-26 SM SM20220205T patent/SMT202200205T1/it unknown
- 2012-10-26 SI SI201231056T patent/SI2770822T1/sl unknown
- 2012-10-26 ES ES17171524T patent/ES2774488T3/es active Active
- 2012-10-26 PT PT191895333T patent/PT3590332T/pt unknown
- 2012-10-26 PT PT128061991T patent/PT2770822T/pt unknown
- 2012-10-26 LT LTEP17171524.6T patent/LT3272214T/lt unknown
- 2012-10-26 EP EP19189533.3A patent/EP3590332B1/en active Active
- 2012-10-26 MX MX2014004896A patent/MX355726B/es active IP Right Grant
- 2012-10-26 ES ES19189533T patent/ES2914374T3/es active Active
- 2012-10-26 CA CA2852962A patent/CA2852962C/en active Active
- 2012-10-26 CN CN201810239690.4A patent/CN108707608A/zh active Pending
- 2012-10-26 SI SI201231738T patent/SI3272214T1/sl unknown
- 2012-10-26 HU HUE12806199A patent/HUE034374T2/en unknown
- 2012-10-26 PT PT171715246T patent/PT3272214T/pt unknown
- 2012-10-26 HU HUE17171524A patent/HUE048511T2/hu unknown
- 2012-10-26 JP JP2014539027A patent/JP6285361B2/ja active Active
- 2012-10-26 SG SG10201510056SA patent/SG10201510056SA/en unknown
- 2012-10-26 PL PL19189533T patent/PL3590332T3/pl unknown
- 2012-10-26 SG SG10201909638U patent/SG10201909638UA/en unknown
- 2012-10-26 DK DK19189533.3T patent/DK3590332T3/da active
- 2012-10-26 RS RS20170897A patent/RS56330B1/sr unknown
- 2012-10-26 HR HRP20171327TT patent/HRP20171327T1/hr unknown
- 2012-10-26 CN CN201810239986.6A patent/CN108401986B/zh active Active
- 2012-10-26 RS RS20200224A patent/RS59997B1/sr unknown
- 2012-10-26 RS RS20220473A patent/RS63220B1/sr unknown
- 2012-10-26 HR HRP20220616TT patent/HRP20220616T1/hr unknown
- 2012-10-26 SG SG11201400938UA patent/SG11201400938UA/en unknown
- 2012-10-26 RU RU2014116577A patent/RU2660564C2/ru active
- 2012-10-26 WO PCT/US2012/062029 patent/WO2013063340A1/en not_active Ceased
- 2012-10-26 AU AU2012327205A patent/AU2012327205B2/en active Active
- 2012-10-26 SM SM20200114T patent/SMT202000114T1/it unknown
- 2012-10-26 DK DK17171524.6T patent/DK3272214T3/da active
- 2012-10-26 KR KR1020147014315A patent/KR101926442B1/ko active Active
- 2012-10-26 IN IN3892CHN2014 patent/IN2014CN03892A/en unknown
- 2012-10-26 SI SI201231999T patent/SI3590332T1/sl unknown
- 2012-10-26 ES ES12806199.1T patent/ES2640241T3/es active Active
- 2012-10-26 US US13/661,116 patent/US8847005B2/en active Active
- 2012-10-26 KR KR1020187034955A patent/KR102113108B1/ko active Active
-
2014
- 2014-04-03 IL IL231895A patent/IL231895B/en active IP Right Grant
- 2014-08-08 US US14/455,237 patent/US9585373B2/en active Active
-
2016
- 2016-01-11 IL IL243565A patent/IL243565A/en active IP Right Grant
- 2016-04-13 AU AU2016202317A patent/AU2016202317B2/en active Active
-
2017
- 2017-01-24 US US15/413,785 patent/US10219493B2/en active Active
- 2017-08-17 JP JP2017157497A patent/JP6652529B2/ja active Active
- 2017-09-05 CY CY20171100934T patent/CY1119283T1/el unknown
-
2018
- 2018-02-27 AU AU2018201402A patent/AU2018201402C1/en active Active
- 2018-06-21 IL IL260209A patent/IL260209B/en active IP Right Grant
-
2019
- 2019-01-10 US US16/244,892 patent/US11219195B2/en active Active
- 2019-01-10 US US16/244,912 patent/US10986822B2/en active Active
-
2020
- 2020-02-24 HR HRP20200305TT patent/HRP20200305T1/hr unknown
- 2020-02-26 CY CY20201100178T patent/CY1122700T1/el unknown
-
2021
- 2021-01-22 AU AU2021200438A patent/AU2021200438B2/en active Active
- 2021-03-17 US US17/204,526 patent/US20210195878A1/en not_active Abandoned
-
2022
- 2022-05-20 CY CY20221100349T patent/CY1125196T1/el unknown
-
2024
- 2024-07-23 US US18/781,796 patent/US20240365761A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL231895B (en) | Transgenic mice expressing chimeric mhc type ii molecules | |
| IL261239B (en) | Mice with mhc genetic changes | |
| IL274914A (en) | Mice with a genetic change in the T cell receptor |